Finally, while we excluded acute heart failure trials such as EMPULSE [25] to maintain homogeneity, the findings regarding SGLT2 inhibitors in the chronic setting are relevant along the continuum of heart failure care. The gene discussed is SLC5A2; the disease is heart failure.